A new COVID-19 vaccine, cheaper than other brands, is now entering clinical trials in Thailand, Vietnam, and Mexico. The developers of this new medicine claim that the new NDV-HXP-S coronavirus vaccine is very different from other COVID-19 shots.
According to The New York Times' latest report, the medical innovation is the first vaccine that uses a new molecular design. This new technology could allow NDV-HXP-S to produce more potent antibodies than the current COVID-19 medicines such as Sinovac, Moderna, Johnsons and Johnsons, and more.
Unlike Pfizer and other coronavirus vaccines, which need to be produced in specialized factories using ingredients that are very difficult to acquire, the new NDV-HXP-S vaccine will be mass-produced in chicken eggs.
What makes the NDV-HXP-S COVID-19 vaccine different
Yahoo Finance reported that the new cheap vaccine will come from chicken eggs, which is the same process that experts use to make influenza vaccines for the past years. Since it is easier to produce compared to other brands, the developers could make billion of doses of the new NDV-HXP-S vaccine.
Read also: COVID-19 Could Also Endanger Bats: Here's How Likely Humans to Transmit the Virus to Them
However, this will only happen once its clinical trials prove that it is effective and safe for human use. The new COVID-19 vaccine will be very essential for middle-income and low-income countries, which are currently struggling to purchase the expensive COVID-19 shots from wealthier nations.
"That's staggering - it would be a game-changer," said Duke Global Health Innovation Center's Assistant Director Andrea Taylor.
"It's a home run for protection. I think it's a world-class vaccine," added the medical expert.
Will it be available globally?
As of the moment, the new cheap vaccine is still completing its clinical trials.
UT News confirmed that it is the product of global partners that want to provide people with advanced and more affordable vaccines. These include the Icahn School of Medicine at Mount Sinai in New York, The University of Texas at Austin, and more.
On the other hand, PATH, a global organization, is now helping the vaccine's developers so that they could soon have global access. If you want to know more details, just click here.
For more news updates about COVID-19 vaccines and other related studies, always keep your tabs open here at TechTimes.
This article is owned by TechTimes
Written by: Giuliano de Leon
